Aggressive B-Cell Non-Hodgkin Lymphoma — Trials

Aggressive B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

400 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 115
Recruiting: 56
Ph III recruiting: 1
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (72)

clinicaltrialsPublishedShowing 51–68 of 68 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05674175	Co-administration of CART22-65s and huCART19 for B-ALL	recruiting	Phase 1 / Phase 2	93	Stephan Grupp MD PhDOTHER	1	Mar 27, 2026	clinicaltrials
NCT02446457	Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	active not recruiting	Phase 2	53	M.D. Anderson Cancer CenterOTHER	1	Mar 9, 2026	clinicaltrials